Japanese Generics Ready Major Launches This Summer
This article was originally published in PharmAsia News
Japanese makers of generic drugs plan major launches of their products this summer, but no branded drug is expected to attract as much attention as Pfizer's Amlodipine (amlodipine besylate) for treating hypertension. A total of 38 companies have clearance from Japan's Health Ministry to sell a generic version of Amlodipine, the country's best-selling drug whose patent protection expired in March. Sawai's version is expected on the market in July. (Click here for more - a subscription may be required
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.